Journal
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume 19, Issue 1, Pages E33-E36Publisher
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2018.08.021
Keywords
AL amyloidosis; Antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7); Autologous peripheral blood stem cell collection and transplant; Hematological and organ response; Nephrotic range proteinuria
Categories
Ask authors/readers for more resources
Elotuzumab, an immunostimulatory monoclonal antibody targeting a signaling lymphocytic activation molecule F7 (SLAMF7), has been approved for patients with relapsed or refractory multiple myeloma (MM) in combination with lenalidomide, and dexamethasone. However, little is known regarding the use of elotuzumab for the treatment of immunoglobulin light chain amyloidosis with MM. We report the treatment of a patient with multiple relapsed MM and immunoglobulin light chain amyloidosis with ERD. This patient had a dramatic decrease in kappa free light chain and nephrotic range proteinuria after previous progressions on multiple lines of therapy. (C) 2018 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available